Clinical Trial Update: Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia [Phase 1]

View source ↗

Summary

Phase 1 study characterizing intramuscular four-week long-acting injectable risperidone injections in the buttock of patients with schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• risperidone long-acting injectable (4-week formulation) (risperidone)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Psychotic Disorders, Schizophrenia | Phase 1 | Status: COMPLETED